PIOfix-study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia

Diabetes Technology and Therapeutics

Volumn 13, Issue 6, 2011, Pages 637-643

  Pfützner, Andreas ^a,b,h   Schöndorf, Thomas ^a,b   Tschöpe, Diethelm ^c   Lobmann, Ralf ^d   Merke, Jürgen ^e   Müller, Jürgen ^f   Lehmann, Ute ^g   Fuchs, Winfried ^g   Forst, Thomas ^a  

^a Institute for Clinical Research and Development   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Bürgerspital Hospital   (Germany)

^e Diabetes Practice   (Germany)

^f acromion GmbH   (Germany)

^g Takeda Pharma GmbH   (Germany)

^h IKFE GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS PIOGLITAZONE; PROINSULIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; PROINSULIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 79957581477     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2010.0233     Document Type: Article

References (26)

1. Krauss RM, Siri PW: Dyslipidemia in type 2 diabetes. Med Clin North Am 2004;88:897-909. (Pubitemid 39090344)
2. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G: Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-174. (Pubitemid 40467663)
3. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28: 1547-1554. (Pubitemid 40923063)
4. Leonhardt W, Pfützner A, Müller J, Pietzsch J, Forst T, Karagiannis E, Lübben G, Hanefeld M: Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: a sub-analysis from the PIOSTAT study. Atherosclerosis 2008;201:155-162.
5. Hanefeld M, Marx N, Pfützner A, Baurecht W, Luebben G, Kargiannis E, Stier U, Forst T: Anti-inflammatory effect of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitive CRP: the PIOSTAT study. J Am Coll Cardiol 2007;49:291-298.
6. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Köhler C, Baurecht W, Hohberg C, Hanefeld M: Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism 2007;56:491-496. (Pubitemid 46437254)
7. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780. (Pubitemid 46629127)
8. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J; PROactive Investigators: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive. Stroke 2007;38:865-873.
9. Karim A, Slater M, Bradford D, Schwartz L, Zhao Z, Cao C, Laurent A: Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug. J Clin Pharmacol 2007;47:37-47. (Pubitemid 44973996)
10. Perez A, Zhao Z, Jacks R, Spanheimer R: Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009;25: 2915-2923.
11. Schöndorf T, Karagiannis E, Posseldt RE, Forst T, Pfützner A: Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone-results from a post-marketing surveillance trial under daily routine conditions. Diabetes Technol Ther 2009;11:379-383.
12. Hedblad B, Nilsson P, Janzon L, Berglund G: Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. Diabet Med 2000;17:299-307. (Pubitemid 30266125)
13. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. (Pubitemid 351831357)
14. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559. (Pubitemid 351831356)
15. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139. Erratum in: N Engl J Med 2009;361:1028.
16. Cannon CP: Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone 2007;8:11-28. (Pubitemid 351597781)
17. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393. (Pubitemid 36159355)
18. Pfützner A, Weber MM, Forst T: Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. Expert Opin Pharmacother 2007;8:1985-1998. (Pubitemid 47333523)
19. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791. (Pubitemid 34655345)
20. Pfützner A, Kunt T, Mondok A, Pahler S, Konrad T, Luebben G, Forst T: Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004;27:682-687. (Pubitemid 38280533)
21. Schöndorf T, Maiworm A, Emisson N, Forst T, Pfützner A: Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab 2005;51: 489-494. (Pubitemid 41644187)
22. Pfützner A, Forst T: High-sensitivity C-reactive peptide as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006;8:28-36.
23. Pfützner A, Weber MM, Forst T: A biomarker concept for assessment of insulin resistance, b-cell function and chronic systemic inflammation in type 2 diabetes mellitus. Clin Lab 2008;54:485-490.
24. Forst T, Hohberg C, Pfützner A: Cardiovascular effects of disturbed insulin metabolism in metabolic syndrome and type 2 diabetes patients. Horm Metab Res 2009;41: 123-131.
25. Demeterco C, Hao E, Lee SH, Itkin-Ansari P, Levine F: Adult human beta-cell neogenesis? Diabetes Obes Metab 2009; 11(Suppl 4):6-53.
26. Meshkani R, Adeli K: Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42: 1331-1346.